This article was originally published in The Gray Sheet
Executive SummaryHealth Care Financing Administration assigns a HCPCS product code and reimbursement rate for the company's PLAS+SD transfusion plasma product. The system utilizes a solvent detergent process to inactivate deadly viruses such as HIV, hepatitis C and hepatitis B in plasma. Effective July 1, the rate has been set at $169, representing a $60 premium over the reimbursement rate for untreated fresh frozen plasma. According to the company, approximately 50-60% of procedures are done on Medicare patients and sales are expected to benefit from the new code
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.